Status:

ACTIVE_NOT_RECRUITING

Ivabradine for Prevention of Myocardial Injury After Noncardiac Surgery Trial (PREVENT-MINS)

Lead Sponsor:

Jagiellonian University

Collaborating Sponsors:

Population Health Research Institute

Vanderbilt University Medical Center

Conditions:

Myocardial Injury After Noncardiac Surgery (MINS)

Myocardial Ischemia

Eligibility:

All Genders

45+ years

Phase:

PHASE3

Brief Summary

This study is a multicentre, randomized controlled trial of ivabradine versus placebo.

Detailed Description

The PREVENT-MINS study is a 2,500 patient multicentre, superiority randomized controlled trial of ivabradine versus placebo. The primary objective of the trial is to determine the impact of ivabradine...

Eligibility Criteria

Inclusion

  • Undergoing noncardiac surgery
  • ≥45 years of age
  • Expected to require at least an overnight hospital admission after surgery
  • Provide written informed consent to participate in the PREVENT-MINS Trial, AND
  • Fulfill ≥1 of the following 5 criteria (A-E):
  • A. History of coronary artery disease B. History of peripheral arterial disease C. History of stroke D. Undergoing major vascular surgery, OR
  • E. Any 3 of 9 risk criteria:
  • i. Undergoing major surgery ii. History of congestive heart failure iii. History of a transient ischaemic attack iv. Diabetes and currently taking an oral hypoglycemic agent or insulin v. Age ≥70 years vi. History of hypertension vii. Serum creatinine \>175 µmol/L (\>2.0 mg/dl) viii. History of smoking within 2 years of surgery ix. Undergoing emergent/urgent surgery

Exclusion

  • Conduction abnormalities:
  • A. Non-sinus rhythm on ECG B. Sinoatrial or AV (2nd and 3d degree) blocks C. Sick sinus syndrome D. Long QT syndrome E. Pacemaker dependent
  • Transplanted heart (or on waiting list)
  • Use of a selected class I or III antiarrhythmic drug (quinidine, disopyramide, sotalol, ibutilide, amiodarone) or diltiazem/verapamil
  • Resting heart rate \<65 beats per minute on the day of surgery
  • Systolic blood pressure \<90 mmHg on the day of surgery
  • Acute decompensated heart failure, cardiogenic shock, acute myocarditis
  • Acute coronary syndrome within 2 months before surgery;
  • Stroke or transient cerebral ischaemia within 1 month before surgery
  • Known severe liver or kidney disease (MDRD creatinine clearance \<15 mL/min)
  • Inability to tolerate oral intake
  • Recent use of ivabradine (\<1 month)
  • Known allergy or hypersensitivity to ivabradine
  • Low-risk surgical procedure based on individual physician's judgment
  • Investigator considers the patient unreliable regarding requirement for study compliance
  • Women of childbearing potential who are not taking effective contraception, pregnant or breast-feeding
  • Previously enrolled in the PREVENT-MINS study

Key Trial Info

Start Date :

June 13 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 30 2026

Estimated Enrollment :

2146 Patients enrolled

Trial Details

Trial ID

NCT05279651

Start Date

June 13 2022

End Date

June 30 2026

Last Update

September 3 2025

Active Locations (26)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 7 (26 locations)

1

Szpital Uniwersytecki nr 1 im. dr Antoniego Jurasza w Bydgoszczy

Bydgoszcz, Poland, 85-094

2

Specjalistyczny Szpital Wojewódzki w Ciechanowie

Ciechanów, Poland, 06-400

3

ZZOZ Szpital Śląski w Cieszynie

Cieszyn, Poland, 43-400

4

Uniwersyteckie Centrum Kliniczne Gdańskiego Uniwersytetu Medycznego

Gdansk, Poland, 80-952

Ivabradine for Prevention of Myocardial Injury After Noncardiac Surgery Trial (PREVENT-MINS) | DecenTrialz